IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ('IGC' or the 'Company') today announced that it presented its latest scientific poster, titled 'Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay,' at the 2025 Genetic Toxicology Association Annual Meeting, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ('API') in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.
'This is an important milestone, as we prepare the drug for larger trials and eventual commercialization. The geno-tox data was presented at the annual conference on Genetic Toxicology held in Delaware, on May 8, 2025.' Said Ram Mukunda CEO of IGC Pharma.
This GLP-compliant study, conducted by an independent lab in Canada, evaluated the API's mutagenic potential using the Bacterial Reverse Mutation Test (commonly known as the Ames test), as part of a broader genetic toxicology battery. The study assessed multiple bacterial strains (Salmonella typhimurium TA1535, TA1537, TA98, TA100 and Escherichia coli WP2 trp uvrA) both in the presence (+S9) and absence (-S9) of an exogenous mammalian metabolic activation system, as per OECD Guideline 471 and ICH S2(R1) recommendations.
At various concentrations ranging from 1.6 to 5000 µg/plate, no evidence of mutagenicity was observed at any dose level. Across all strains and experimental conditions, Fold Response values remained below 2-the established threshold for mutagenic activity. Revertant colony counts remained within the range of the negative controls and substantially lower than the positive controls, confirming assay validity. Additionally, statistical analysis using Dunnett's test showed no significant dose-related increases (p > 0.05), reinforcing the conclusion that the API does not induce gene mutations under the tested conditions.
To access the full poster or learn more about IGC Pharma's ongoing research, please visit the LINK.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial ( CALMA ) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ('SEC') filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: IGC Pharma, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
8 minutes ago
- Forbes
How CPAs Should Speak To Clients As Crypto Adoption Accelerates
CPAs need to be educated on crypto to better advise clients CPAs have been discussing crypto for years, but given the rapidly (and positively) changing regulatory and policy environment it seems a good time to revisit what might sound like a straight-forward question; how should CPAs approach clients about cryptoassets? While in the past CPAs could have reasonably advised clients to minimize exposure to crypto since the regulatory environment was so uncertain, bankruptcies such as FTX dominated the headlines, and price volatility seemed ingrained into the asset class. Over the last 12-18 months, however, those narratives have changed significantly, with several developments making the crypto conversation between advisors and clients much more nuanced. Positive momentum on the legislative front at the federal and numerous state levels, the proliferation of spot crypto ETFs, the relaxation of previous strict language around including crypto into 401 (k) plans, the comprehensive repayment plans announced by the FTX estate, and the successful IPO of major stablecoin issuer Circle have all contributed to a more optimistic for crypto as 2025 continues to roll forward. Despite these developments, including the actions taken by the OCC and FDIC to allow more institutions to engage with crypto operations, the tax and accounting outlook for crypto has yet to significantly shift. Let's take a look at a few things CPAs need to keep in mind when discussing crypto with clients as positive momentum continues to accelerate. Given the nearly continuous flow of positive headlines around cryptoassets and the increased frequency with which investors of all sizes are allocating funds to said assets CPAs might very well be speaking with clients who fear missing out on these returns. That said, the investing adage that past success does not indicate future performance holds equally as true for crypto as any other asset class. For example, bitcoin has traded as low as $70,000 in 2025 prior to rebounding back about $100,000 beginning in May 2025; volatility remains an embedded part of the crypto ecosystem. For CPA clients seeking to integrate cryptoassets as part of a treasury allocation, accepting cryptoassets for payment purposes, or seeking to advise external clients whether crypto is a good fit for operations the pressure to invest in crypto can be significant. A responsibility of CPAs across the board is to make sure that any and all clients interested in crypto are only investing in these assets if the assets are well understood, and are a good fit for the business model of the firm. Despite the positive changes that have permeated into the cryptoasset sector the tax ramifications of these the fact remains that taxes are an obstacle to wider utilization of crypto for business purposes. Virtually every single transaction, transformation, or exchange that involves cryptoassets will create a tax reporting and potential tax payment obligation, and this has not changed even as the usage and adoption of crypto continues to accelerate. This is especially true for individuals that engage in higher volume trading or business activities, as several changes in particular will impact businesses using crypto. Specifically, changes that are related to IRS code section 6045 and 6050I, including the pivot to a universal wallet tracking methodology, are set to complicate the accounting for crypto transactions and gains. With further changes coming to the marketplace beginning January 2026, and while DeFi broker regulations (with an effective date in 2027) have been sidelined for now, the tax conversation around crypto is far from over. CPAs are already trusted as business and tax advisors, and especially as it is connected to crypto the value that can be added to a client via improved tax information is difficult to overstate. An often repeated issue and statement that can arise with the onboarding of cryptoassets is the perception that internal controls are less important since underlying blockchains are usually perceived as immutable and unhackable. Even if the blockchain itself has proven itself resilient and impervious to hacking attempts the multitude of hacks and data breaches that have occurred in the cryptoasset sector should serve as a reminder that internal controls are always important. Specifically the recent data breach at Coinbase should be illustrative to potential users and investors in crypto; even one of the most highlight regulated and well regarded institutions in the crypto sector suffered a data breach due to social engineering attacks on certain employees. For smaller institutions or entrepreneurs looking to gain exposure to crypto the importance of establishing and improving internal controls around cryptoassets and crypto policies should be an imperative. CPAs are well versed in assisting clients in the establishment and improvement of controls and control frameworks, and the importance of controls around crypto is no different. Crypto continues to make inroads across the economic board, and CPAs need to be well-prepared to discuss these issues with clients now and going forward.
Washington Post
27 minutes ago
- Washington Post
Video shows dolphin calf birth and first breath at Chicago zoo. Mom's friend helped
CHICAGO — A bottlenose dolphin at a Chicago zoo gave birth to a calf early Saturday morning with the help of a fellow mom, in a successful birth recorded on video by zoo staff. The dolphin calf was born at Brookfield Zoo Chicago early Saturday morning as a team of veterinarians monitored and cheered on the mom, a 38-year-old bottlenose dolphin named Allie. 'Push, push, push,' one observer can be heard shouting in video released by the zoo Saturday, as Allie swims around the tank, the calf's little tail fins poking out below her own. Then the calf wriggles free and instinctively darts to the surface of the pool for its first breath. Also in the tank was an experienced mother dolphin named Tapeko, 43, who stayed close to Allie through her more than one hour of labor. In the video, she can be seen following the calf as it heads to the surface, and staying with it as it takes that first breath. It is natural for dolphins to look out for each other during a birth, zoo staff said. 'That's very common both in free-ranging settings but also in aquaria,' said Brookfield Zoo Chicago Senior Veterinarian Dr. Jennifer Langan in a video statement. 'It provides the mom extra protection and a little bit of extra help to help get the calf to the surface to help it breath in those couple minutes where she's still having really strong contractions.' In a written statement, zoo officials said early signs indicate that the calf is in good health. They estimate it weighs around 35 pounds (16 kilograms) and stretches nearly four feet in length (115-120 centimeters). That is about the weight and length of an adult golden retriever dog. The zoo's Seven Seas exhibit will be closed as the calf bonds with its mother and acclimates with other dolphins in its group. As part of that bonding, the calf has already learned to slipstream, or draft alongside its mother so that it doesn't have to work as hard to move. Veterinarians will monitor progress in nursing, swimming and other milestones particularly closely over the next 30 days. The calf will eventually take a paternity test to see which of the male dolphins at the zoo is its father. Zoo officials say they will name the calf later this summer.
CBS News
30 minutes ago
- CBS News
Bay Area pressed penny souvenir business facing end of penny production in 2026
San Francisco Pressed Penny Souvenir business reacts to the end of the penny San Francisco Pressed Penny Souvenir business reacts to the end of the penny San Francisco Pressed Penny Souvenir business reacts to the end of the penny For Matt Sengbusch's business, dollars have never made sense, but coins do — particularly the penny. He uses them to operate more than 50 penny pressing machines throughout the Bay Area. The most popular one is located on Pier 39. People pay 51 cents for the machine to press pictures of tourist attractions into stretched pennies. It's a pocket-sized souvenir that can last a lifetime. But soon, finding pennies to use might be more pressing than the machine. The U.S. Mint in late May said that they've ordered their last copper stock to make the penny. The decision came from President Donald Trump in February, citing costs. The coin costs more to make than it's worth. The US spends about 4 cents for every penny, which is only valued at 1 cent. The move is expected to save the US $56 million a year, but it'll cost Sengbusch dearly. He makes between $10,000 to $15,000 annually from the business. "The other part of this, besides pennies, is the quarters," Sengbusch said. He supplies businesses on the pier with quarters, and as for the pennies, he said he plans to buy copper blanks to replace the penny. "If it were just for the money, I wouldn't do it," he said. But business aside, moving away from the penny represents a break with tradition and a parting with a staple of US history, which is something he doesn't know if he's ready to embrace. "These are like the last pennies ever, like new ones," Sengbusch said, opening a new roll of pennies. Penny production will stop in 2026, forever changing the landscape of the coin-operated world Sengbusch loves. He said he will keep using them until the coin falls out of circulation. For now, it just makes sense.
